These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38565461)

  • 1. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.
    Koschinsky ML; Bajaj A; Boffa MB; Dixon DL; Ferdinand KC; Gidding SS; Gill EA; Jacobson TA; Michos ED; Safarova MS; Soffer DE; Taub PR; Wilkinson MJ; Wilson DP; Ballantyne CM
    J Clin Lipidol; 2024; 18(3):e308-e319. PubMed ID: 38565461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein apheresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA
    Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
    Vogt A
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HEART UK consensus statement on Lipoprotein(a): A call to action.
    Cegla J; Neely RDG; France M; Ferns G; Byrne CD; Halcox J; Datta D; Capps N; Shoulders C; Qureshi N; Rees A; Main L; Cramb R; Viljoen A; Payne J; Soran H;
    Atherosclerosis; 2019 Dec; 291():62-70. PubMed ID: 31704552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) and mortality-a high risk relationship.
    Klingel R; Heibges A; Fassbender C
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):13-19. PubMed ID: 30838554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
    Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.
    Moriarty PM; Gray JV; Gorby LK
    J Clin Lipidol; 2019; 13(6):894-900. PubMed ID: 31753721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
    Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.
    Stulnig TM; Morozzi C; Reindl-Schwaighofer R; Stefanutti C
    Curr Atheroscler Rep; 2019 Jul; 21(10):37. PubMed ID: 31350625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study.
    Madsen CM; Kamstrup PR; Langsted A; Varbo A; Nordestgaard BG
    Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):255-266. PubMed ID: 31578080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.
    Burgess S; Ference BA; Staley JR; Freitag DF; Mason AM; Nielsen SF; Willeit P; Young R; Surendran P; Karthikeyan S; Bolton TR; Peters JE; Kamstrup PR; Tybjærg-Hansen A; Benn M; Langsted A; Schnohr P; Vedel-Krogh S; Kobylecki CJ; Ford I; Packard C; Trompet S; Jukema JW; Sattar N; Di Angelantonio E; Saleheen D; Howson JMM; Nordestgaard BG; Butterworth AS; Danesh J;
    JAMA Cardiol; 2018 Jul; 3(7):619-627. PubMed ID: 29926099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
    Mickiewicz A; Marlega J; Kuchta A; Bachorski W; Cwiklinska A; Raczak G; Gruchala M; Fijalkowski M
    J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
    Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein(a) as a cardiovascular risk factor: current status.
    Nordestgaard BG; Chapman MJ; Ray K; Borén J; Andreotti F; Watts GF; Ginsberg H; Amarenco P; Catapano A; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A;
    Eur Heart J; 2010 Dec; 31(23):2844-53. PubMed ID: 20965889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical management of dyslipidemia with elevated lipoprotein(a).
    Riche DM; East HE; Priest HM
    J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.